BriaCell Therapeutics Corp. (BCTX)
NASDAQ: BCTX · Real-Time Price · USD
0.8090
-0.0210 (-2.53%)
At close: Jul 24, 2025, 4:00 PM
0.8000
-0.0090 (-1.11%)
After-hours: Jul 24, 2025, 7:41 PM EDT

BriaCell Therapeutics Stock Forecast

BCTX's stock price has decreased by -92.34% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 1 analyst with a 12-month price forecast for BriaCell Therapeutics stock has a target of 32, which predicts a 3855.5% increase from the current stock price of 0.81.

Price Target: $32 (+3855.5%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$32$32$32$32
Change+3855.5%+3855.5%+3855.5%+3855.5%
* Price targets were last updated on Apr 22, 2025.

Analyst Ratings

According to 1 stock analyst, the rating for BriaCell Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingFeb '25Mar '25Apr '25May '25Jun '25Jul '25
Strong Buy111111
Buy000000
Hold000000
Sell000000
Strong Sell000000
Total111111

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$32
Strong BuyReiterates$32+3,855.50%Apr 22, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$15$32
Strong BuyMaintains$15$32+3,855.50%Feb 3, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$225
Strong BuyReiterates$225+27,712.11%Dec 12, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$225
Strong BuyReiterates$225+27,712.11%Dec 3, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$225
Strong BuyReiterates$225+27,712.11%Oct 3, 2024
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-5.29
from -4.37
EPS Next Year
-1.79
from -5.29
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingJul 31, 2020Jul 31, 2021Jul 31, 2022Jul 31, 2023Jul 31, 2024Jul 31, 2025Jul 31, 2026Jul 31, 2027
Revenue
--10.20M
Revenue Growth
--------
EPS
-84.56-45.85-25.98-19.50-4.37-5.29-1.79-1.45
EPS Growth
--------
Forward PE
--------
No. Analysts
-----322
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue202520262027
Highn/an/a10.6M
Avgn/an/a10.2M
Lown/an/a9.9M

Revenue Growth

Revenue Growth202520262027
High---
Avg---
Low---

EPS Forecast

EPS202520262027
High-2.76-1.86-1.51
Avg-5.29-1.79-1.45
Low-7.68-1.73-1.41

EPS Growth

EPS Growth202520262027
High---
Avg---
Low---
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.